PEG-g-chitosan nanoparticles functionalized with the monoclonal antibody OX26 for brain drug targeting

Nanomedicine

Volumn 10, Issue 11, 2015, Pages 1735-1750

  Monsalve, Yuliana ^a   Tosi, Giovanni ^b   Ruozi, Barbara ^b   Belletti, Daniela ^b   Vilella, Antonietta ^b   Zoli, Michele ^b   Vandelli, Maria Angela ^b   Forni, Flavio ^b   López, Betty L ^a   Sierra, Ligia ^a  

^a UNIVERSIDAD DE ANTIOQUIA   (Colombia)

^b UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

Author keywords

blood brain barrier; chitosan; drug targeting; monoclonal antibody OX26; nanoparticles

Indexed keywords

ACID ANHYDRIDE; CHITOSAN NANOPARTICLE; FLUORESCEIN ISOTHIOCYANATE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY OX26; PEG G CHITOSAN NANOPARTICLE; UNCLASSIFIED DRUG; CHITOSAN; MACROGOL DERIVATIVE; NANOPARTICLE;

ANIMAL EXPERIMENT; ARTICLE; BLOOD BRAIN BARRIER; CENTRAL NERVOUS SYSTEM; CHEMICAL MODIFICATION; CONJUGATION; DRUG BRAIN LEVEL; DRUG DELIVERY SYSTEM; DRUG TARGETING; IN VIVO STUDY; MOUSE; NONHUMAN; PARTICLE SIZE; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; SYNTHESIS; ANIMAL; BRAIN; CHEMISTRY; DRUG EFFECTS; HUMAN;

ANIMALS; ANTIBODIES, MONOCLONAL; BLOOD-BRAIN BARRIER; BRAIN; CENTRAL NERVOUS SYSTEM; CHITOSAN; DRUG DELIVERY SYSTEMS; HUMANS; MICE; NANOPARTICLES; POLYETHYLENE GLYCOLS;

EID: 84931827816     PISSN: 17435889     EISSN: 17486963     Source Type: Journal    
DOI: 10.2217/nnm.15.29     Document Type: Article

References (55)

1. Masserini M. Nanoparticles for brain drug delivery. ISRN Biochemistry 2013, 1-18 (2013).
2. Gabathuler R. Approaches to transport therapeutic drugs across the blood-brain barrier to treat brain diseases. Neurobiol. Dis. 37(1), 48-57 (2010).
3. Hervé F, Ghinea N, Scherrmann J-M. CNS delivery via adsorptive transcytosis. AAPS J. 10(3), 455-472 (2008).
4. Wang Y-Y, Lui PCW, Li JY. Receptor-mediated therapeutic transport across the blood-brain barrier. Immunotherapy 1(6), 983-993 (2009).
5. Tosi G, Badiali L, Ruozi B et al. Can leptin-derived sequence-modified nanoparticles be suitable tools for brain delivery? Nanomedicine (Lond.) 7(3), 365-382 (2012).
6. Jain S, Mishra V, Singh P, Dubey PK, Saraf DK, Vyas SP. RGD-anchored magnetic liposomes for monocytes/neutrophils-mediated brain targeting. Int. J. Pharm. 261(1-2), 43-55 (2003).
7. Nhan T, Burgess A, Cho EE, Stefanovic B, Lilge L, Hynynen K. Drug delivery to the brain by focused ultrasound induced blood-brain barrier disruption: quantitative evaluation of enhanced permeability of cerebral vasculature using twophoton microscopy. J. Control. Release 172(1), 274-280 (2013).
8. Aryal M, Arvanitis CD, Alexander PM, McDannold N. Ultrasound-mediated blood-brain barrier disruption for targeted drug delivery in the central nervous system. Adv. Drug Deliv. Rev. 72C, 94-109 (2014).
9. Wu X-Y, Li X-C, Mi J, You J, Hai L. Design, synthesis and preliminary biological evaluation of brain targeting l-ascorbic acid prodrugs of ibuprofen. Chinese Chem. Lett. 24(2), 117-119 (2013).
10. Celia C, Cosco D, Paolino D, Fresta M. Nanoparticulate devices for brain drug delivery. Med. Res. Rev. 31(5), 716-756 (2010).
11. Patel T, Zhou J, Piepmeier JM, Saltzman WM. Polymeric nanoparticles for drug delivery to the central nervous system. Adv. Drug Deliv. Rev. 64(7), 701-705 (2012).
12. Tosi G, Bortot B, Ruozi B et al. Potential use of polymeric nanoparticles for drug delivery across the blood-brain barrier. Curr. Med. Chem. 20(17), 2212-2225 (2013).
13. Tosi G, Ruozi B, Belletti D et al. Brain-targeted polymeric nanoparticles: in vivo evidence of different routes of administration in rodents. Nanomedicine (Lond.) 8(9), 1373-1383 (2013).
14. Das D, Lin S. Double-coated poly (butylcynanoacrylate) nanoparticulate delivery systems for brain targeting of dalargin via oral administration. J. Pharm. Sci. 94(6), 1343-1353 (2005).
15. Liu Z, Gao X, Kang T et al. B6 peptide modified PEG-PLA nanoparticles for enhanced brain. Bioconjug. Chem. 24(6), 997-1007 (2013).
16. Gosk S, Vermehren C, Storm G, Moos T. Targeting antitransferrin receptor antibody (OX26) and OX26-conjugated liposomes to brain capillary endothelial cells using in situ perfusion. J. Cereb. Blood Flow Metab. 24(11), 1193-1204 (2004).
17. Akta? Y, Yemisci M, Andrieux K et al. Development and brain delivery of chitosan-PEG nanoparticles functionalized with the monoclonal antibody OX26. Bioconjug. Chem. 16(6), 1503-1511 (2005).
18. Ulbrich K, Hekmatara T, Herbert E, Kreuter J. Transferrinand transferrin-receptor-antibody-modified nanoparticles enable drug delivery across the BBB. Eur. J. Pharm. Biopharm. 71(2), 251-256 (2009).
19. Rodrigues S, Dionísio M, López CR, Grenha A. Biocompatibility of chitosan carriers with application in drug delivery. J. Funct. Biomater. 3(4), 615-641 (2012).
20. Kean T, Thanou M. Biodegradation, biodistribution and toxicity of chitosan. Adv. Drug Deliv. Rev. 62(1), 3-11 (2010).
21. Mohammed MH, Williams PA, Tverezovskaya O. Extraction of chitin from prawn shells and conversion to low molecular mass chitosan. Food Hydrocolloids 31(2), 166-171 (2013).
22. Shukla SK, Mishra AK, Arotiba OA, Mamba BB. Chitosanbased nanomaterials: a state-of-the-art review. Int. J. Biol. Macromol. 59, 46-58 (2013).
23. Park JH, Saravanakumar G, Kim K, Kwon IC. Targeted delivery of low molecular drugs using chitosan and its derivatives. Adv. Drug Deliv. Rev. 62(1), 28-41 (2010).
24. Wang JJ, Zeng ZW, Xiao RZ et al. Recent advances of chitosan nanoparticles as drug carriers. Int. J. Nanomed. 6, 765-774 (2011).
25. Saboktakin MR, Tabatabaie RM, Maharramov A, Ramazanov MA. Synthesis and in vitro evaluation of carboxymethyl starch-chitosan nanoparticles as drug delivery system to the colon. Int. J. Biol. Macromol. 48(3), 381-385 (2011).
26. Abdelghany SM, Schmid D, Deacon J et al. Enhanced antitumor activity of the photosensitizer meso-Tetra(Nmethyl-4-pyridyl) porphine tetra tosylate through encapsulation in antibody-targeted chitosan/alginate nanoparticles. Biomacromolecules 14(2), 302-310 (2013).
27. Lee J, Yun K, Choi CS et al. T Cell-Speci fi c siRNA Delivery using antibody-conjugated chitosan nanoparticles. Bioconjug. Chem. 23(6), 1174-1180 (2012).
28. Owens DE, Peppas NA. Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles. Int. J. Pharm. 307(1), 93-102 (2006).
29. Liu L, Guo K, Lu J et al. Biologically active core/shell nanoparticles self-assembled from cholesterol-terminated PEG-TAT for drug delivery across the blood-brain barrier. Biomaterials 29(10), 1509-1517 (2008).
30. Huang R, Ma H, Guo Y et al. Angiopep-conjugated nanoparticles for targeted long-term gene therapy of Parkinson's disease. Pharm. Res. 30(10), 2549-2559 (2013).
31. Van der Meel R, Vehmeijer LJC, Kok RJ, Storm G, van Gaal EVB. Ligand-targeted particulate nanomedicines undergoing clinical evaluation: current status. Adv. Drug Deliv. Rev. 65(10), 1284-1298 (2013).
32. Nagpal K, Singh SK, Mishra D. Evaluation of safety and efficacy of brain targeted chitosan nanoparticles of minocycline. Int. J. Biol. Macromol. 59, 20-28 (2013).
33. Garcia-Fuentes M, Alonso MJ. Chitosan-based drug nanocarriers: where do we stand? J. Control. Release 161(2), 496-504 (2012).
34. Gorzelanny C, Pöppelmann B, Pappelbaum K, Moerschbacher BM, Schneider SW. Human macrophage activation triggered by chitotriosidase-mediated chitin and chitosan degradation. Biomaterials 31(33), 8556-8563 (2010).
35. Carreño-Gómez B, Duncan R. Evaluation of the biological properties of soluble chitosan and chitosan microspheres. Int. J. Pharm. 148(2), 231-240 (1997).
36. US National Institutes of Health. ClinicalTrials.gov. https://clinicaltrials.gov
37. Huang M, Khor E, Lim L-Y. Uptake and cytotoxicity of chitosan molecules and nanoparticles: effects of molecular weight and degree of deacetylation. Pharm. Res. 21(2), 344-353 (2004).
38. Malhotra M, Saha S, Kahouli I, Prakash S. Development and characterization of chitosan-PEG-TAT nanoparticles for the intracellular delivery of siRNA. Int. J. Nanomed. 8, 2041-2052 (2013).
39. Yemi?ci M, Yasemin G-Ö, Caban S, Bodur E, Çapan Y, Dalkara T. Transport of a caspase inhibitor across the blood-brain barrier by chitosan nanoparticles. Methods Enzymol. 508, 253-269 (2012).
40. Huang C, Chen Y. Coagulation of colloidal particles in water by chitosan. J. Chem. Technol. Biotechnol. 66(3), 227-232 (1996).
41. Aziz H, Ramli S. Potential use of chitosan as coagulant in removing suspended solids, chemical oxygen demand, colour and turbidity from land fill leachate. In: International Conference on Industrial Engineering and Management Science-2013. Chen X, Sun YM (Eds). DEstech Publication, Inc., PA, USA, 936-941 (2013).
42. Alonso MJ, Calvo P, Remun C. Novel hydrophilic chitosan-polyethylene oxide nanoparticles as protein carriers. J. Appl. Polym. Sci. 63(1), 125-132 (1997).
43. Baek SH, Kim B, Suh K Do. Chitosan particle/multiwall carbon nanotube composites by electrostatic interactions. Colloids Surf. A Physicochem. Eng. Asp. 316(1-3), 292-296 (2008).
44. Bao H, Li L, Zhang H. Influence of cetyltrimethylammonium bromide on physicochemical properties and microstructures of chitosan-TPP nanoparticles in aqueous solutions. J. Colloid Interface Sci. 328(2), 270-277 (2008).
45. Patel PN, Patel LJ, Patel JK, Vidyadham SPS. Development and testing of novel temoxifen citrate loaded chitosan nanoparticles using ionic gelation method. Pelagia Res. Libr. 2(4), 17-25 (2011).
46. Costantino L, Gandolfi F, Tosi G, Rivasi F, Vandelli MA, Forni F. Peptide-derivatized biodegradable nanoparticles able to cross the blood-brain barrier. J. Control. Release 108(1), 84-96 (2005).
47. Vilella A, Tosi G, Grabrucker AM et al. Insight on the fate of CNS-targeted nanoparticles. Part I: Rab5-dependent cell-specific uptake and distribution. J. Control. Release 174, 195-201 (2014).
48. Tosi G, Vilella A, Chhabra R et al. Insight on the fate of CNS-targeted nanoparticles. Part II: intercellular neuronal cell-to-cell transport. J. Control. Release 177, 96-107 (2014).
49. Collins TJ. ImageJ for microscopy. Biotechniques 43, S25-S30 (2007).
50. Zoli Michele, Guidolin Diego and Agnati Luigi F. Morphometric evaluation of populations of neuronal profiles (cell bodies, dendrites, and nerve terminals) in the central nervous system. Microsc. Res. Tech. 21(4), 315-337 (1992).
51. Vanichvattanadecha C, Supaphol P, Nagasawa N et al. Effect of gamma radiation on dilute aqueous solutions and thin films of N-succinyl chitosan. Polym. Degrad. Stabil. 95(2), 234-244 (2010).
52. Xu P, Bajaj G, Shugg T, Van Alstine WG, Yeo Y. Zwitterionic chitosan derivatives for pH-sensitive stealth coating. Biomacromolecules 11(9), 2352-2358 (2010).
53. Bhumkar DR, Pokharkar VB. Studies on effect of pH on cross-linking of chitosan with sodium tripolyphosphate: a technical note. AAPS PharmSciTech. 7(2), E50 (2006).
54. Yue J, Liu S, Wang R et al. Fluorescence-labeled immunomicelles: preparation, in vivo biodistribution, and ability to cross the blood-brain barrier. Macromol. Biosci. 12(9), 1209-1219 (2012).
55. Pang Z, Lu W, Gao H et al. Preparation and brain delivery property of biodegradable polymersomes conjugated with OX26. J. Control. Release 128(2), 120-127 (2008).